Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA | MRNA Price Prediction) and Merck (NYSE:MRK) came back positive, yet the selling hasn't stopped. Those numbers landed short of the loftiest hopes built into a long rally.

Pfizer's dividend yield ranks among the highest in the healthcare sector and S&P 500. Bristol Myers Squibb maintains a more comfortable payout ratio than Pfizer, though.

Both companies pay relatively high-yield dividends. One marries this with growing fundamentals, while the other is basically in reset mode.

Pfizer currently generates a higher volume of absolute revenue, while Bristol Myers Squibb displays a more consistent baseline without the recent negative fluctuations seen by the former. Over the last eight quarters, Pfizer experienced fluctuating quarter-over-quarter results with multiple periods of year-over-year contraction, whereas Bristol Myers Squibb maintained a steadier trajectory characterized by continuous year-over-year growth.

A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked favorable on their face. Moderna stock is at $184.

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before you chase the bigger payout, the coverage numbers behind each dividend tell a very different story.

In the latest trading session, Pfizer (PFE) closed at $30.11, marking a +2.28% move from the previous day.

Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.